to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
Many patents are valuable assets and are worth the time and money spent in obtaining them. This topic overview asserts entrepreneurs should undertake an objective analysis of a potential patent's value prior to filing an application to avoid investing in a possibly worthless asset.
The launch of a new product is analogous to the birth of a child, necessitating commitment, preparation, the ability to set a date against which to measure progress, and finally delivery, writes the author. Illustrative are scenes from this entrepreneur's introduction of physician-approved videos aimed at educating patients about their diseases.
Thomas J. Fogarty is a specialist whose creative talents have impacted many diverse professional and entrepreneurial arenas. In addition to his teaching responsibilities as Professor of Surgery at Stanford University,
Dr. Fogarty performs numerous cardiac and peripheral vascular surgeries, manages several medical device companies founded upon his product designs, is founder and active Senior Partner in the venture capital firm of Three Arch Partners,
and also finds time to pursue his interest in oenology at the family owned and operated Thomas Fogarty Winery and Vineyards. During the past 40 years he has acquired over 70 surgical patents, including the "industry standard" Fogarty
balloon embolectomy catheter. Patented in 1969, this first balloon catheter for the vascular system was a sophisticated version of the original crude instrument that young Tom Fogarty, then an OR scrub technician, designed in the late
1950's using a surgical glove finger tied to a ureteral catheter. Other commercially successful medical products designed by the Fogarty engineering group include a minimally invasive device for breast cancer diagnosis and therapy, and
also a self-expanding stent-graft used to treat critical aortic aneurysms via a minimally invasive technique. Dr. Fogarty is a past recipient of the Inventor of the Year award given by the San Francisco Patent and Trademark Association, a
four-time recipient of the Distinguished Scientific Presentation award presented by the American College of Surgeons, and was the first recipient to receive the award for "Achievement in Medicine" bestowed by the Santa Clara County Medical
Association. Selected recent awards include the 2000 Lemelson-MIT $500,000 Prize for Invention and Innovation as well as the Association for Advancement of Medical Instrumentation Foundation's Annual Laufman-Greatbatch Prize for inventing
breakthrough medical devices. Later in 200
Stephen P.A. Fodor is a native of Seattle, Washington. He received his B.S. in Biology and M.S. in Biochemistry from Washington State University and his Ph.D. in Chemistry at Princeton University. From 1986 to 1989, he
was a National Institutes of Health postdoctoral fellow at The University of California, Berkeley, working on time-resolved spectroscopy of bacterial and plant pigments. In 1989 he was recruited to the Affymax Research Institute in Palo
Alto where he spearheaded the effort to develop high-density arrays of biological compounds. Dr. Fodor and colleagues were the first to develop and describe microarray technologies and combinatorial chemistry synthesis. In 1993, Dr. Fodor
co-founded Affymetrix where the chip technology has been used to synthesize many varieties of high density oligonucleotide arrays containing hundreds of thousands of DNA probes. These DNA chips have broad commercial applications and are
now used in many areas of basic and clinical research including the detection of drug resistance mutations in infectious organisms, direct DNA sequence comparison of large segments of the human genome, the monitoring of multiple human
genes for cancer associated mutations, the quantitative and parallel measurement of mRNA expression for thousands of human genes, and the physical and genetic mapping of the human genome. In 2001, Dr. Fodor founded Perlegen, Inc., a new
venture that applied the chip technology on uncovering the basic patterns of human diversity. The adoption of the technology by both commercial and research institutions for these and other applications continues to grow
Jesse Fink is a founding partner of MissionPoint Capital and President and CEO of Marshall Street Management. In 2004, MSM established MSM Capital Partners to manage its investment activities in the clean technology and
environmental finance sectors. Jesse was the COO of Walker Digital Inc. and Priceline.com and previously worked at Georgia-Pacific, Citicorp, and CUC International. Jesse received a B.S. in Resource Management from the State University of
New York's College of Environmental Science and Forestry and an MBA from Syracuse University's School of Management. In February of 2007, Jesse received the Cleantech Venture Network's "Leader of the Year" award.
One of the best ways to grow your company is to provide your customers with such a great experience that they return again.
Customers may be motivated to purchase a product or service just by reading a price list.
The prices you charge of one of the most critical components of your product and service features set, and affects nearly every aspect of your business, including your cash flow, sales numbers, and profits.
This article describes a process to conduct primary market research, such as gathering information and data from customers, suppliers, vendors, as well as your own employees.
When evaluating industry potential, key considerations include its current size and rate of growth as well as profitability characteristics and trends.
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.